系统性硬化症疾病进展的纵向自身抗体与蛋白质组特征
研究纳入30例基线和49例随访的系统性硬化症初治患者及38例对照,用120种自身抗原微阵列和DIA质谱分析自身抗体与蛋白质组动态变化。自身抗体滴度升高者88.9%出现疾病进展,CENP-B滴度升高与进展强相关(HR 5.036);SERPINA10为最强进展风险因素,ENTPD5最具保护性。
要点
- 自身抗体滴度动态变化较基线水平与SSc疾病轨迹关联更强。
- CENP-B滴度升高与疾病进展强相关(HR 5.036)。
- SERPINA10为最强进展风险因素,ENTPD5最具保护性。
核心结论
- 自身抗体滴度的动态变化而非基线水平与SSc疾病轨迹关联更强。
- 蛋白质组特征提示脂质代谢和氧化应激可能是疾病进展的潜在驱动因素,为SSc个性化管理提供新生物标志物和治疗靶点。
研究设计与样本
- 纳入30例基线、49例随访的系统性硬化症初治患者及38例对照,分析血清样本。
- 采用靶向120种自身抗体的自身抗原微阵列评估自身抗体谱,并以数据非依赖采集模式的液相色谱质谱进行蛋白质组分析。
- 使用Cox比例风险模型评估与疾病进展的关联,采用Spearman相关分析抗体-蛋白相互作用。
主要发现
- 基线自身抗体谱识别出高表达(SSc_high)和低表达(SSc_low)两个患者亚组,但两组临床特征相似。
- 纵向分析显示,自身抗体滴度升高的患者中88.9%出现疾病进展,而滴度下降的患者中60%显示临床改善。
- CENP-B滴度升高与疾病进展强相关(风险比5.036)。
- 滴度下降且临床改善的患者中鉴定出112种参与组织修复和免疫调节的蛋白质,而滴度升高且疾病进展者中富集46种与脂质代谢和氧化应激相关的蛋白质。
- SERPINA10为最强的进展风险因素,ENTPD5最具保护性;并发现包括SERPINE1和毒蕈碱受体抗体在内的抗体-蛋白相关性。
关键数值与推荐
- 自身抗体滴度升高患者中88.9%出现疾病进展,滴度下降患者中60%显示临床改善。
- CENP-B滴度升高与疾病进展的风险比为5.036。
- 滴度下降且临床改善者中鉴定出112种组织修复和免疫调节相关蛋白质,滴度升高且进展者中富集46种脂质代谢和氧化应激相关蛋白质。
- SERPINA10为最强进展风险因素,ENTPD5最具保护性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate dynamic changes in autoantibody and proteomic profiles in treatment-naïve patients with systemic sclerosis (SSc) and to identify biomarkers and mechanisms associated with disease progression. METHODS: Serum samples from 30 baseline and 49 follow-up patients with SSc, along with 38 controls, were analyzed. Autoantibody profiles were assessed using an autoantigen microarray targeting 120 autoantibodies, whereas proteomic analysis was conducted via liquid chromatography mass spectrometry in data-independent acquisition mode. Cox proportional hazards models were used to assess associations with disease progression, and Spearman's correlation was applied to analyze antibody-protein interactions. RESULTS: Baseline autoantibody profiling identified two patient subgroups: high expression (SSc_high) and low expression (SSc_low), though their clinical characteristics were similar. Longitudinal analysis revealed that 88.9% of patients with rising autoantibody titers experienced disease progression, whereas 60% of those with decreasing titers showed clinical improvement. Notably, increased CENP-B titers (hazard ratio 5.036) were strongly linked to disease progression. Proteomic analysis identified 112 proteins involved in tissue repair and immune modulation in patients with declining titers and clinical improvement, whereas 46 proteins linked to lipid metabolism and oxidative stress were enriched in those with rising titers and disease progression. SERPINA10 emerged as the strongest risk factor for progression, whereas ENTPD5 was most protective. Antibody-protein correlations that highlight key molecular interactions, including SERPINE1 and muscarinic receptor antibodies, were identified. CONCLUSION: Dynamic changes in autoantibody titers, rather than baseline levels, were more strongly associated with SSc trajectory. Proteomic signatures suggest lipid metabolism and oxidative stress as potential drivers, highlighting novel biomarkers and therapeutic targets for personalized SSc management.
引用
- Guo M, Liu S, Huang J, et al. Longitudinal Autoantibody and Proteomic Signatures of Disease Progression in Systemic Sclerosis. Arthritis Rheumatol. 2025. PMID: 40928059. doi:10.1002/art.43354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。